SPIRARE II Post Hoc Analyses Presented for Jupiter Endovascular’s Vertex Thrombectomy System

November 3, 2026—Jupiter Endovascular, Inc., announced findings from post hoc analyses of its SPIRARE II pivotal trial examining pulmonary artery (PA) pressure and right ventricular (RV) recovery after treatment with the company’s Vertex thrombectomy system for pulmonary embolism (PE).

Primary Endpoint Results Presented From Medtronic’s SPYRAL AFFIRM Postapproval RDN Study

November 3, 2026—Medtronic announced that the SPYRAL AFFIRM postapproval study of its Symplicity Spyral renal denervation (RDN) system met its primary endpoint, demonstrating statistically significant reductions in office, home, and 24-hour ambulatory systolic blood pressure at 6 months in patients with uncontrolled hypertension.

The PERT Consortium Names Mark McIlduff as Executive Director

November 3, 2026—The PERT Consortium announced the appointment of Mark McIldiff as Executive Director.

Concept’s MagicTouch PTA SCB Evaluated in Femoropopliteal Disease in 3-Year SIRONA Data

November 3, 2026—Concept Medical announced the presentation of 3-year results from the randomized SIRONA trial of patients with femoropopliteal artery disease treated with percutaneous transluminal angioplasty (PTA) using the company’s MagicTouch PTA sirolimus-coated balloon (SCB).

Penumbra’s Lightning Flash 3.0 CAVT System Receives CE Mark Approval

November 2, 2026—Penumbra announced it has received CE Mark approval for the Lightning Flash 3.0 computer-assisted vacuum thrombectomy (CAVT) system, which includes significant upgrades to advance the company’s venous thromboembolism platform.

Inquis Medical Launches SENSE-PE Registry of Aventus Thrombectomy System

November 2, 2026—Inquis Medical announced the launch of SENSE-PE, a postmarket registry evaluating the safety and efficacy of the company’s Aventus thrombectomy system in patients with acute pulmonary embolism (PE).

AMA Advances Framework for Clinical AI Liability

October 30, 2026—The American Medical Association (AMA) announced that its Center for Digital Health and Artificial Intelligence (AI) is advancing a new framework for aligning liability in clinical care with each party’s (developers and manufacturers; health care organizations and other deployers; physicians; and patients) authority and ability to prevent or mitigate harm.

Rampart Launches Vanguard Total-Body Radiation Protection for Interventional Imagers

October 29, 2026—Rampart announced the launch of Vanguard, a radiation protection solution designed for interventional imagers working at the head of the table.